John M. Leonard - Net Worth and Insider Trading
John M. Leonard Net Worth
The estimated net worth of John M. Leonard is at least $46 Million dollars as of 2023-09-26. John M. Leonard is the President and CEO of Intellia Therapeutics Inc and owns about 825,240 shares of Intellia Therapeutics Inc (NTLA) stock worth over $27 Million. John M. Leonard is the SVP, Chief Scientific Officer of AbbVie Inc and owns about 113,793 shares of AbbVie Inc (ABBV) stock worth over $18 Million. John M. Leonard is also the Director of IQVIA Holdings Inc and owns about 8,252 shares of IQVIA Holdings Inc (IQV) stock worth over $2 Million. Besides these, John M. Leonard also holds Chimerix Inc (CMRX) . Details can be seen in John M. Leonard's Latest Holdings Summary section.
Transaction Summary of John M. Leonard
John M. Leonard Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John M. Leonard owns 5 companies in total, including Intellia Therapeutics Inc (NTLA) , IQVIA Holdings Inc (IQV) , and Chimerix Inc (CMRX) among others .
Click here to see the complete history of John M. Leonard’s form 4 insider trades.
Insider Ownership Summary of John M. Leonard
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| NTLA | Intellia Therapeutics Inc | 2020-03-02 | director & President and CEO |
| IQV | IQVIA Holdings Inc | 2015-02-05 | director |
| CMRX | Chimerix Inc | 2014-06-20 | director |
| VTAE | Vitae Pharmaceuticals Inc | 2016-10-25 | director |
| ABBV | AbbVie Inc | 2012-12-07 | SVP & Chief Scientific Officer |
John M. Leonard Latest Holdings Summary
John M. Leonard currently owns a total of 4 stocks. Among these stocks, John M. Leonard owns 825,240 shares of Intellia Therapeutics Inc (NTLA) as of January 4, 2023, with a value of $27 Million and a weighting of 57.97%. John M. Leonard owns 113,793 shares of AbbVie Inc (ABBV) as of March 15, 2013, with a value of $18 Million and a weighting of 38.38%. John M. Leonard also owns 8,252 shares of IQVIA Holdings Inc (IQV) as of December 20, 2019, with a value of $2 Million and a weighting of 3.64%. The other 1 stocks Chimerix Inc (CMRX) have a combined weighting of 0% among all his current holdings.
Latest Holdings of John M. Leonard
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NTLA | Intellia Therapeutics Inc | 2023-01-04 | 825,240 | 32.21 | 26,580,980 |
| ABBV | AbbVie Inc | 2013-03-15 | 113,793 | 154.65 | 17,598,087 |
| IQV | IQVIA Holdings Inc | 2019-12-20 | 8,252 | 202.39 | 1,670,122 |
| CMRX | Chimerix Inc | 2016-09-15 | 0 | 0.98 | 0 |
Holding Weightings of John M. Leonard
John M. Leonard Form 4 Trading Tracker
According to the SEC Form 4 filings, John M. Leonard has made a total of 18 transactions in Intellia Therapeutics Inc (NTLA) over the past 5 years, including 0 buys and 18 sells. The most-recent trade in Intellia Therapeutics Inc is the sale of 6,673 shares on January 4, 2023, which brought John M. Leonard around $248,302.
According to the SEC Form 4 filings, John M. Leonard has made a total of 0 transactions in AbbVie Inc (ABBV) over the past 5 years. The most-recent trade in AbbVie Inc is the sale of 46,700 shares on March 15, 2013, which brought John M. Leonard around $2 Million.
According to the SEC Form 4 filings, John M. Leonard has made a total of 1 transactions in IQVIA Holdings Inc (IQV) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in IQVIA Holdings Inc is the sale of 20,200 shares on December 20, 2019, which brought John M. Leonard around $3 Million.
More details on John M. Leonard's insider transactions can be found in the Insider Trading History of John M. Leonard table.Insider Trading History of John M. Leonard
- 1
John M. Leonard Trading Performance
GuruFocus tracks the stock performance after each of John M. Leonard's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John M. Leonard is -11.82%. GuruFocus also compares John M. Leonard's trading performance to market benchmark return within the same time period. The performance of stocks bought by John M. Leonard within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John M. Leonard's insider trading performs compared to the benchmark.
Performance of John M. Leonard
Average Relative Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Relative Return(%) | -0.43 | -11.82 | -83.57 | -90.72 | -69.13 | -55.01 |
| Relative Return to S&P 500(%) | -0.23 | -17.82 | -80.88 | -101.53 | -80.11 | -68.25 |
John M. Leonard Ownership Network
Ownership Network List of John M. Leonard
Ownership Network Relation of John M. Leonard
John M. Leonard Owned Company Details
What does Intellia Therapeutics Inc do?
Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Who are the key executives at Intellia Therapeutics Inc?
John M. Leonard is the director & President and CEO of Intellia Therapeutics Inc. Other key executives at Intellia Therapeutics Inc include EVP & Chief Technical Officer Eliana Clark , EVP & Chief Business Officer Derek Hicks , and EVP & General Counsel James Basta .
Intellia Therapeutics Inc (NTLA) Insider Trades Summary
Over the past 18 months, John M. Leonard made 1 insider transaction in Intellia Therapeutics Inc (NTLA) with a net sale of 6,673. Other recent insider transactions involving Intellia Therapeutics Inc (NTLA) include a net sale of 7,388 shares made by Eliana Clark , a net sale of 2,132 shares made by Muna Bhanji , and a net sale of 4,838 shares made by Laura Sepp-lorenzino .
In summary, during the past 3 months, insiders sold 2,492 shares of Intellia Therapeutics Inc (NTLA) in total and bought 0 shares, with a net sale of 2,492 shares. During the past 18 months, 28,982 shares of Intellia Therapeutics Inc (NTLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 28,982 shares.
Intellia Therapeutics Inc (NTLA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Intellia Therapeutics Inc Insider Transactions
John M. Leonard Mailing Address
Above is the net worth, insider trading, and ownership report for John M. Leonard. You might contact John M. Leonard via mailing address: C/o Intellia Therapeutics Inc, 40 Erie Street, Suite 130, Cambridge Ma 02139.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
